 NOVATO, Calif., May 18, 2021 GLOBE NEWSWIRE -- Ultragenyx Pharmaceutical Inc. NASDAQ: RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 4,677 shares of common stock of the company and 7,100 restricted stock units of the companys common stock to a newly hired non-executive officer of the company. The awards were approved by the compensation committee of the companys board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2021, as an inducement material to the new employee entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635c4. 